Compare McDonald's Corp (MCD) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? McDonald's Corp trades at $234.48 (market cap $167.64B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.66 (market cap $58.74B). The key difference: McDonald's Corp is far larger — about 2.9× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| MCD | TAK | |
|---|---|---|
Market Cap | $167.64B | $58.74B |
Volume | 11,320,306 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $19.05 |
52-Week Low | $230.88 | $13.23 |
Typical Hold Time | 164 Days | 0 Days |
Enterprise Value | $221.41B | $86.65B |
Dividend Yield | 3.26% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $230.88, down 0.68% on the day, with a bearish technical signal from moving averages. The company shows steady revenue growth, reaching $26.89B in 2025, and has consistently beaten EPS estimates in recent quarters. Recent news highlights a new global growth strategy, 'McDonald's NEXT', focusing on automation and improved customer experience to counter competitive pressures and attract diners.
The outlook is mixed: strong fundamentals and a 58.7% analyst buy rating support upside to the $284.70 consensus target, but technical weakness and inflation-driven cost pressures pose near-term risks. The stock offers value through its dividend and defensive profile, yet investors must weigh execution risks of the new strategy against its long-term growth potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
